Corrigendum to “Imatinib: A Breakthrough of Targeted Therapy in Cancer”
- (i)
S. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” School of Pharmacy, 37, 5 (Oncology suppl): 3–7, 2012 (https://www.uspharmacist.com/article/targeted-therapies-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia) [2] (not cited).
- (ii)
A. Olivieri, M. Cimminiello, P. Corradini, et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” Blood, 2013, doi: https://doi.org/10.1182/blood-2013-05-494278 (http://www.bloodjournal.org/content/122/25/4111) [3] (cited as reference 56).
- (iii)
C. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” Leukemia Research, 2011, doi: https://doi.org/10.1016/j.leukres.2011.05.006 (https://www.lrjournal.com/article/S0145-2126(11)00223-2/fulltext) [4] (not cited).
- (iv)
S. Verstovsek, “New Hematological Indications for Imatinib,” Hematological Cancer, 2007, doi: http://doi.org/10.17925/OHR.2007.00.2.36 (https://www.touchoncology.com/articles/new-hematological-indications-imatinib) [5] (not cited).
- (v)
M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” Cardiovascular and Hematological Disorders-Drug Targets, 2009, doi: https://doi.org/10.2174/187152909787581363 (http://www.eurekaselect.com/68887/article) [6] (not cited).
